Table 13.
Efficacy of 12.5 mg ombitasvir + 75 mg paritaprevir + 50 mg ritonavir fixed-dose two pills QD plus 250 mg dasabuvir BID for 12w.
| Cirrhosis | Prior treatment | SVR12 in GT-1 | Study and trial phase | Ref. |
|---|---|---|---|---|
| No cirrhosis |
Naïve | 88.6% (70/79) a | AVIATOR, phase 2b | Kowdley et al., 2014b |
| Null response | 1b: 100% (32/32) | PEARL-II, phase 3 | Andreone et al., 2014 | |
| Partial response | 1b: 100% (26/26) | |||
| Relapse | 1b: 100% (33/33) | |||
| Naïve | 1a: 90.2% (185/205), 1b:99% (207/209) | PEARL-IV, PEARL-III, phase 3 | Ferenci et al., 2014 | |
| Naïve, stage 4 or 5 chronic kidney disease | 1b: 100% (7/7) | RUBY-I, phase 3 | Pockros et al., 2016 | |
| Naïve | 1b: 97.6% (81/83) | MALACHITE-I, phase 3 | Dore et al., 2016a | |
| Naïve | 1b: 97.8% (391/400) | Real-world study |
Ioannou et al., 2016 |
|
| Experienced | 1b: 99% (103/104) | |||
| Cirrhosis | Naïve | 1b: 100% (27/27) | TURQUOISE-III, phase 3b | Feld et al., 2016b |
| Experienced | 1b: 100% (33/33) | |||
| Naïve | 1b: 100% (24/24) | Real-world study | Ioannou et al., 2016 | |
a
SVR24 rates were evaluated in the clinical study.